2025 Q4 -tulosraportti
Vain PDF
69 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 5 000 | - | - | ||
| 250 | - | - | ||
| 3 000 | - | - | ||
| 4 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·49 min sittenSAN DIEGO IS NOT THE FINISH LINE. IT IS WHERE THE SEEDS ARE SOWN. 🌱 People are waiting for BIO to "deliver" this week. As if a conference is a finish line where something is decided on the spot. That's not how it works. And when you understand why, you stop stressing. BIO is not the harvest. It is the sowing. What's happening in San Diego now are hundreds of conversations. Meetings. First handshakes. People learning what circVec actually is, taking it back to their teams, starting to think. No one signs a billion-dollar deal over a coffee at a fair. But almost every single deal in this industry starts with such a coffee. The seed is sown here. The tree grows in the months after — in the lab, in internal evaluations, in follow-up meetings none of us see. And the fruit? It's picked later. When it's ripe. In its own time. Just as ASGCT was not the finish line — it was the data that planted the interest which became the feasibility study we have today. Same pattern. Sow, grow, harvest. The impatient one sees a quiet week and gets disappointed. The patient one knows that the most important seeds are planted precisely in such weeks — long before anyone sees anything grow. We sow now. We harvest later. We know what we own. ♟️🧱🍷And just to balance my own point 🌱 — that the fruit is picked later doesn't mean it always takes forever. Sometimes things grow faster than one realizes. A seed sown on BIO can meet a partner who has already been looking for exactly this — and then the conversation moves quickly. When something meets a real need with the right player, it can move much faster than standard timelines would suggest. So both are true at the same time: it can take longer than we hope, and it can go faster than we think. No one knows which way it will go — and that's precisely why you just have to own it and be patient. The point is not to guess the date. The point is that we have the seeds planted, many tables in play, and a cash box that allows us to wait until the fruit is ripe — whether it takes three months or eighteen. Patient, but alert. 🍷♟️
·3 t sitten · MuokattuThis is what Grok says right now, on the question of whether anything exciting is happening in Circio right now. . Yes, quite a lot of exciting things are happening in Circio right now! Circio Holding ASA (formerly Targovax, ticker CRNA on the Oslo Stock Exchange) is a Norwegian biotech company that is heavily investing in circular RNA (circRNA) technology to improve gene and cell therapy. They have had a real turnaround in 2026 with significant financial and technological advancements. The main news right now (June 2026): Major fundraising success: They have secured around NOK 300 million through warrant exercise and an underwritten private placement. In total, they have raised approx. NOK 620 million (approx. USD 65 million) in the first half of 2026. This gives them runway until 2030 and the opportunity to significantly scale up R&D. The share capital has recently been adjusted and registered, and the stock has been active (around 8–8.5 NOK level recently, with high volatility typical for biotech). Technology and pipeline: They are developing the circVec platform – a circular RNA-based gene expression technology designed to provide stronger, more stable, and cost-effective gene expression compared to traditional mRNA/AAV. They have shown promising data such as up to 40–50x improved expression in heart and eye tissue. Upcoming milestones include: PoC for therapeutic constructs in Q2 2026 In vivo data for CNS and disease models in the second half of 2026 Collaboration with major pharma companies (e.g., feasibility study with a top 5 global player) They are also participating in important conferences such as BIO 2026 in San Diego now (June 22–25). In short: Circio is in a transformational phase with solid financing, technological progress, and ambitious plans to become a leader in circular RNA for gene therapy. These are definitely exciting times for those following biotech in Norway! Would you like more details about the stock, pipeline, or a specific press release? 😊
·4 t sitten · MuokattuWhat are people doing? Selling off shares at 7.39 in a week where company management is in the USA to meet stakeholders, seems completely insane. That the price is now up 0.40 from today's lowest and will surely go up even more before closing time, must be a nightmare to see for those who sold and thus miss out on around 0.50 per share. Hard to grasp what's going through people's heads.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
69 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sittenSAN DIEGO IS NOT THE FINISH LINE. IT IS WHERE THE SEEDS ARE SOWN. 🌱 People are waiting for BIO to "deliver" this week. As if a conference is a finish line where something is decided on the spot. That's not how it works. And when you understand why, you stop stressing. BIO is not the harvest. It is the sowing. What's happening in San Diego now are hundreds of conversations. Meetings. First handshakes. People learning what circVec actually is, taking it back to their teams, starting to think. No one signs a billion-dollar deal over a coffee at a fair. But almost every single deal in this industry starts with such a coffee. The seed is sown here. The tree grows in the months after — in the lab, in internal evaluations, in follow-up meetings none of us see. And the fruit? It's picked later. When it's ripe. In its own time. Just as ASGCT was not the finish line — it was the data that planted the interest which became the feasibility study we have today. Same pattern. Sow, grow, harvest. The impatient one sees a quiet week and gets disappointed. The patient one knows that the most important seeds are planted precisely in such weeks — long before anyone sees anything grow. We sow now. We harvest later. We know what we own. ♟️🧱🍷And just to balance my own point 🌱 — that the fruit is picked later doesn't mean it always takes forever. Sometimes things grow faster than one realizes. A seed sown on BIO can meet a partner who has already been looking for exactly this — and then the conversation moves quickly. When something meets a real need with the right player, it can move much faster than standard timelines would suggest. So both are true at the same time: it can take longer than we hope, and it can go faster than we think. No one knows which way it will go — and that's precisely why you just have to own it and be patient. The point is not to guess the date. The point is that we have the seeds planted, many tables in play, and a cash box that allows us to wait until the fruit is ripe — whether it takes three months or eighteen. Patient, but alert. 🍷♟️
- ·3 t sitten · MuokattuThis is what Grok says right now, on the question of whether anything exciting is happening in Circio right now. . Yes, quite a lot of exciting things are happening in Circio right now! Circio Holding ASA (formerly Targovax, ticker CRNA on the Oslo Stock Exchange) is a Norwegian biotech company that is heavily investing in circular RNA (circRNA) technology to improve gene and cell therapy. They have had a real turnaround in 2026 with significant financial and technological advancements. The main news right now (June 2026): Major fundraising success: They have secured around NOK 300 million through warrant exercise and an underwritten private placement. In total, they have raised approx. NOK 620 million (approx. USD 65 million) in the first half of 2026. This gives them runway until 2030 and the opportunity to significantly scale up R&D. The share capital has recently been adjusted and registered, and the stock has been active (around 8–8.5 NOK level recently, with high volatility typical for biotech). Technology and pipeline: They are developing the circVec platform – a circular RNA-based gene expression technology designed to provide stronger, more stable, and cost-effective gene expression compared to traditional mRNA/AAV. They have shown promising data such as up to 40–50x improved expression in heart and eye tissue. Upcoming milestones include: PoC for therapeutic constructs in Q2 2026 In vivo data for CNS and disease models in the second half of 2026 Collaboration with major pharma companies (e.g., feasibility study with a top 5 global player) They are also participating in important conferences such as BIO 2026 in San Diego now (June 22–25). In short: Circio is in a transformational phase with solid financing, technological progress, and ambitious plans to become a leader in circular RNA for gene therapy. These are definitely exciting times for those following biotech in Norway! Would you like more details about the stock, pipeline, or a specific press release? 😊
- ·4 t sitten · MuokattuWhat are people doing? Selling off shares at 7.39 in a week where company management is in the USA to meet stakeholders, seems completely insane. That the price is now up 0.40 from today's lowest and will surely go up even more before closing time, must be a nightmare to see for those who sold and thus miss out on around 0.50 per share. Hard to grasp what's going through people's heads.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 5 000 | - | - | ||
| 250 | - | - | ||
| 3 000 | - | - | ||
| 4 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
69 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sittenSAN DIEGO IS NOT THE FINISH LINE. IT IS WHERE THE SEEDS ARE SOWN. 🌱 People are waiting for BIO to "deliver" this week. As if a conference is a finish line where something is decided on the spot. That's not how it works. And when you understand why, you stop stressing. BIO is not the harvest. It is the sowing. What's happening in San Diego now are hundreds of conversations. Meetings. First handshakes. People learning what circVec actually is, taking it back to their teams, starting to think. No one signs a billion-dollar deal over a coffee at a fair. But almost every single deal in this industry starts with such a coffee. The seed is sown here. The tree grows in the months after — in the lab, in internal evaluations, in follow-up meetings none of us see. And the fruit? It's picked later. When it's ripe. In its own time. Just as ASGCT was not the finish line — it was the data that planted the interest which became the feasibility study we have today. Same pattern. Sow, grow, harvest. The impatient one sees a quiet week and gets disappointed. The patient one knows that the most important seeds are planted precisely in such weeks — long before anyone sees anything grow. We sow now. We harvest later. We know what we own. ♟️🧱🍷And just to balance my own point 🌱 — that the fruit is picked later doesn't mean it always takes forever. Sometimes things grow faster than one realizes. A seed sown on BIO can meet a partner who has already been looking for exactly this — and then the conversation moves quickly. When something meets a real need with the right player, it can move much faster than standard timelines would suggest. So both are true at the same time: it can take longer than we hope, and it can go faster than we think. No one knows which way it will go — and that's precisely why you just have to own it and be patient. The point is not to guess the date. The point is that we have the seeds planted, many tables in play, and a cash box that allows us to wait until the fruit is ripe — whether it takes three months or eighteen. Patient, but alert. 🍷♟️
- ·3 t sitten · MuokattuThis is what Grok says right now, on the question of whether anything exciting is happening in Circio right now. . Yes, quite a lot of exciting things are happening in Circio right now! Circio Holding ASA (formerly Targovax, ticker CRNA on the Oslo Stock Exchange) is a Norwegian biotech company that is heavily investing in circular RNA (circRNA) technology to improve gene and cell therapy. They have had a real turnaround in 2026 with significant financial and technological advancements. The main news right now (June 2026): Major fundraising success: They have secured around NOK 300 million through warrant exercise and an underwritten private placement. In total, they have raised approx. NOK 620 million (approx. USD 65 million) in the first half of 2026. This gives them runway until 2030 and the opportunity to significantly scale up R&D. The share capital has recently been adjusted and registered, and the stock has been active (around 8–8.5 NOK level recently, with high volatility typical for biotech). Technology and pipeline: They are developing the circVec platform – a circular RNA-based gene expression technology designed to provide stronger, more stable, and cost-effective gene expression compared to traditional mRNA/AAV. They have shown promising data such as up to 40–50x improved expression in heart and eye tissue. Upcoming milestones include: PoC for therapeutic constructs in Q2 2026 In vivo data for CNS and disease models in the second half of 2026 Collaboration with major pharma companies (e.g., feasibility study with a top 5 global player) They are also participating in important conferences such as BIO 2026 in San Diego now (June 22–25). In short: Circio is in a transformational phase with solid financing, technological progress, and ambitious plans to become a leader in circular RNA for gene therapy. These are definitely exciting times for those following biotech in Norway! Would you like more details about the stock, pipeline, or a specific press release? 😊
- ·4 t sitten · MuokattuWhat are people doing? Selling off shares at 7.39 in a week where company management is in the USA to meet stakeholders, seems completely insane. That the price is now up 0.40 from today's lowest and will surely go up even more before closing time, must be a nightmare to see for those who sold and thus miss out on around 0.50 per share. Hard to grasp what's going through people's heads.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 5 000 | - | - | ||
| 250 | - | - | ||
| 3 000 | - | - | ||
| 4 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt